a., michael
Pantoprazole has an antioxidant function against reactive oxygen species (ROS). Vincamine, a herbal candidate, is an indole alkaloid of clinical use against brain sclerosis. The aim of the present experiment is to evaluate, on a molecular level for the first time, the value of vincamine in addition to pantoprazole in treating experimentally induced...
Phan, Alexander T Tseng, Alan W Choudhery, Mohammad W Makar, Jelena B Nguyen, Cyrus Farmand, Farbod
Published in
Cureus
Proton-pump inhibitors (PPIs) are commonly utilized in the treatment of upper gastrointestinal bleeds (UGIBs) due to their ability to stabilize blood clot formation. PPIs have been shown to reduce rebleeding after endoscopic hemostasis and reduce signs of bleeding at index endoscopy. While PPIs are well-tolerated and commonly administered to patien...
Stoll, Felicitas Blank, Antje Mikus, Gerd Czock, David Foerster, Kathrin I Hermann, Simon Gümüs, Katja Muhareb, Amin Hummler, Simone Sauter, Max
...
Published in
Clinical pharmacology in drug development
Hydroxychloroquine as a weak basic compound with two amines is strongly enriched in cell compartments with low pH, suggesting that modification of gastric pH by coadministered proton pump inhibitors might reduce its solubility and absorption and thus its efficacy in patients. We addressed this question in a single-center, open-label, randomized, pa...
James, Jerin Rani, Jamuna Sathyanarayanan, Varadarajan Begum, Althab Fayaz, Syed Hussain
Published in
Current drug safety
Pantoprazole is a Proton Pump Inhibitor, commonly used by clinicians all over the world as a gastric acid synthesis inhibitor for a wide variety of gastrointestinal disorders. The efficacy and the safety of the drug are unsurmountable. PPIs are being prescribed nowadays for unapproved indications. It is one of the widely used medications in the wor...
Liu, W T Li, Y F Hsieh, T Y
Published in
Journal of postgraduate medicine
Pembrolizumab (an immune checkpoint inhibitor)-related gastritis and gastric ulcers are rare immune-related adverse events, which are insufficiently treated with proton pump inhibitors (PPIs) therapy alone, and usually require systemic steroid therapy and even other biological agents (such as infliximab) in severe cases. Here, we report a case of 4...
Fourie, Natasha Arnold, Marion Banieghbal, Behrouz Marchant, Samantha Lynn
Published in
African Journal of Paediatric Surgery: AJPS
Context: Previous studies demonstrated faster correction of metabolic derangement associated with hypertrophic pyloric stenosis with pre-operative intravenous (IV) histamine-2 receptor antagonists. Aims: We investigated if similar outcomes are achieved with IV pantoprazole, a proton-pump inhibitor (PPI), including the subgroup of delayed presenters...
Kim, Dongchan Kang, Heeyoung
Published in
Contact dermatitis
Schjørring, Olav L Lange, Theis Krag, Mette Andersen-Ranberg, Nina Christine Meyhoff, Tine S Marker, Søren Klitgaard, Thomas L Estrup, Stine Møller, Morten Hylander Rasmussen, Bodil S
...
Published in
Acta anaesthesiologica Scandinavica
Intensive care unit (ICU) patients receive numerous interventions, but knowledge about potential interactions between these interventions is limited. Co-enrolment in randomized clinical trials represents a unique opportunity to investigate any such interactions. We aim to assess interactions in four randomized clinical trials with overlap in inclus...
Fawzy, Michael A Maher, Sherif A Bakkar, Sally M El-Rehany, Mahmoud A Fathy, Moustafa
Published in
International journal of molecular sciences
Ischemia/reperfusion injury (IRI) in the kidney is the most common cause of acute renal dysfunction through different cell damage mechanisms. This study aimed to investigate, on molecular basics for the first time, the effect of pantoprazole on renal IRI in rats. Different biochemical parameters and oxidative stress markers were assessed. ELISA was...
Smith, Joe S. Mochel, Jonathan P. Soto-Gonzalez, Windy M. Rahn, Rebecca R. Fayne, Bryanna N. Escher, Olivia G. Geletka, Anastasia M. Harvill, Lainey E. Bergman, Joan B. Cox, Sherry
...
Published in
Frontiers in Veterinary Science
Background: Ruminant species are at risk of developing abomasal ulceration, but there is a lack of pharmacokinetic data for anti-ulcer therapies, such as the proton pump inhibitor pantoprazole, in goats. Objective: The primary study objective was to estimate the plasma pharmacokinetic parameters for pantoprazole in adult goats after intravenous adm...